Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of orteronel in nonmetastatic castration-resistant prostate cancer
jRCT2080221969Phase 2
- Sponsor
- Takeda
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orteronel in prostate cancer (PCa), sponsored by Takeda.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080221969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221969.